Literature DB >> 2057352

A convenient approach to the synthesis of medium size oligodeoxyribonucleotides by improved new phosphite method.

H Hosaka1, Y Suzuki, H Sato, S Gug-Kim, H Takaku.   

Abstract

Improvement of the new phosphite method for the synthesis of oligodeoxyribonucleotides using the deoxyribonucleoside 3'-bis(1,1,1,3,3,3- hexafluoro-2-propyl) phosphite unit has been carried out via the hydrolysis and capping steps, without any side reaction products. The new phosphite unit and capping agent, bis(1,1,1,3,3,3-hexafluoro-2-propyl)-2-propyl phosphite, is readily activated by N-methylimdazole under very mild condition on a solid support. This operation involves a one pot reaction, which is an advantage over both the phosphite and H- phosphonate approaches. The mechanism of internucleotidic bond formation of the new phosphite method is also discussed.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2057352      PMCID： PMC328254          DOI： 10.1093/nar/19.11.2935

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN： 0305-1048            Impact factor:   16.971


  15 in total

1.  Letter: Phosphite coupling procedure for generating internucleotide links.

Authors:  R I Letsinger; J L Finnan; G A Heavner; N B Lunsford
Journal:  J Am Chem Soc       Date:  1975-05-28       Impact factor: 15.419

2.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.

Authors:  M Lemaitre; B Bayard; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

4.  Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates.

Authors:  C H Agris; K R Blake; P S Miller; M P Reddy; P O Ts'o
Journal:  Biochemistry       Date:  1986-10-07       Impact factor: 3.162

5.  Control of ribonucleic acid function by oligonucleoside methylphosphonates.

Authors:  P S Miller; C H Agris; L Aurelian; K R Blake; A Murakami; M P Reddy; S A Spitz; P O Ts'o
Journal:  Biochimie       Date:  1985 Jul-Aug       Impact factor: 4.079

6.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Authors:  P C Zamecnik; J Goodchild; Y Taguchi; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

7.  Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.

Authors:  C C Smith; L Aurelian; M P Reddy; P S Miller; P O Ts'o
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

8.  Use of new phosphonylating and coupling agents in the synthesis of oligodeoxyribonucleotides via the H-phosphonate approach.

Authors:  O Sakatsume; H Yamane; H Takaku; N Yamamoto
Journal:  Nucleic Acids Res       Date:  1990-06-11       Impact factor: 16.971

9.  Synthesis of DNA via deoxynucleoside H-phosphonate intermediates.

Authors:  B C Froehler; P G Ng; M D Matteucci
Journal:  Nucleic Acids Res       Date:  1986-07-11       Impact factor: 16.971

10.  Solid-phase synthesis of polynucleotides. III. Synthesis of polynucleotides with defined sequences by the block coupling phosphotriester method.

Authors:  K Miyoshi; T Huang; K Itakura
Journal:  Nucleic Acids Res       Date:  1980-11-25       Impact factor: 16.971
View more
  1 in total

1.  Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus.

Authors:  S G Kim; T Hatta; S Tsukahara; H Nakashima; N Yamamoto; Y Shoji; K Takai; H Takaku
Journal:  Bioorg Med Chem       Date:  1995-01       Impact factor: 3.461
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.